Optimal management of hyperlipidemia in primary prevention of cardiovascular disease

International Journal of Cardiology

Volumn 97, Issue 3, 2004, Pages 355-366

  Raza, Jaffar Ali ^a   Babb, Joseph D ^a   Movahed, Assad ^a  

^a EAST CAROLINA UNIVERSITY   (United States)

Author keywords

Cardiovascular disease; Ezetimibe; Hyperlipidemia; Primary prevention; Statins

Indexed keywords

ACETYLSALICYLIC ACID; AMPRENAVIR; ANTILIPEMIC AGENT; AZITHROMYCIN; CHOLESTEROL; CILOSTAZOL; CLARITHROMYCIN; CLOFIBRATE; COLESTYRAMINE; CYCLOSPORIN; DILTIAZEM; ERYTHROMYCIN; FENOFIBRATE; FLUCONAZOLE; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INDINAVIR; ITRACONAZOLE; KETOCONAZOLE; MEVINOLIN; NEFAZODONE; NELFINAVIR; NICOTINIC ACID; PRAVASTATIN; PROBUCOL; RITONAVIR; SAQUINAVIR; TRIACYLGLYCEROL; UNINDEXED DRUG; VERAPAMIL;

ABDOMINAL PAIN; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CONSTIPATION; DIARRHEA; DIET THERAPY; DYSPEPSIA; FLATULENCE; FLUSHING; GRAPEFRUIT JUICE; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERTENSION; HYPERURICEMIA; LIVER TOXICITY; MORTALITY; MYOPATHY; NAUSEA; PANCREATITIS; PATIENT CARE; PEPTIC ULCER; PRIMARY PREVENTION; PRIORITY JOURNAL; PRURITUS; REVIEW; RHABDOMYOLYSIS; RISK FACTOR; STATISTICAL SIGNIFICANCE; TRIACYLGLYCEROL BLOOD LEVEL; VOMITING;

ANTILIPEMIC AGENTS; CARDIOVASCULAR DISEASES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; PRIMARY PREVENTION;

EID: 9244242038     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijcard.2003.07.039     Document Type: Review

References (161)

1. http://www.cdc.gov/health/cardiov.htm.
2. AHA 2002 Heart and stroke statistical update. 2001;4-5 AHA, Dallas, TX
3. Haust M.D., More R.H. Development of modern theories on the pathogenesis of atherosclerosis. Wissler R.W., Geer J.C. The pathogenesis of atherosclerosis. 1972;1-19 Williams and Wilkins, Baltimore, MD
4. Thannhauser S.J., Magendantz H. The different clinical groups of xanthomatous disease: a clinical physiological study of 22 cases. Ann. Intern. Med. 11:1938;1662-1746
5. Kannel W.B., Castelli W.P., Gordon T., McNamara P.M. Serum cholesterol, lipoproteins, and the risk of coronary heart disease. Ann. Intern. Med. 74:1971;1-12
6. Downs J.R., Clearfield M., Weis S., Whitney E., Shapiro D.R., Beere P.A., et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS, Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA. 279:1998;1615-1622
7. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 344:1994;1383-1389
8. The Scandanavian Simvastatin Survival Study (4S) study group, Neaton J.D., Wentworth D. Serum cholesterol, blood pressure, cigarette smoking, and death from coronary heart disease. Overall findings and differences by age for 316,099 white men. Multiple Risk Factor Intervention Trial Research Group. Arch. Intern. Med. 152:1992;56-64
9. Wilson P.W., Garrison R.J., Castelli W.P., Feinleib M., McNamara P.M., Kannel W.B. Prevalence of coronary heart disease in the Framingham Offspring Study: role of lipoprotein cholesterols. Am. J. Cardiol. 46:1980;649-654
10. Bays H.E., Moore P.B., Drehobl M.A., Rosenblatt S., Toth P.D., Dujovne C.A., et al. Effectiveness and tolerability of ezetimibe in patients with primary hypercholesterolemia: pooled analysis of two phase II studies. Clin. Ther. 23:2001;1209-1230
11. Stein E. The lower the better? Reviewing the evidence for more aggressive cholesterol reduction and goal attainment. Atheroscler. Suppl. 2:2002;19-25
12. Levine G.N., Keaney J.F. Jr., Vita J.A. Cholesterol reduction in cardiovascular disease. Clinical benefits and possible mechanisms. N. Engl. J. Med. 332:1995;512-521
13. Lipid Research Clinics Program The lipid research clinics coronary primary prevention trial results: I. Reduction in incidence of coronary heart disease. JAMA. 251:1984;351-364
14. Verschuren W.M., Jacobs D.R., Bloemberg B.P., Kromhout D., Menotti A., Aravanis C., et al. Serum total cholesterol and long-term coronary heart disease mortality in different cultures. Twenty-five-year follow-up of the seven countries study. JAMA. 274:1995;131-136
15. Hoeg J.M., Brewer H.B. Jr. 3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors in the treatment of hypercholesterolemia. JAMA. 258:1987;3532-3536
16. Shepherd J., Cobbe S.M., Ford I., Isles C.G., Lorimer A.R., MacFarlane P.W., et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N. Engl. J. Med. 333:1995;1301-1307
17. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N. Engl. J. Med. 339:1998;1349-1357
18. The Scandanavian Simvastatin Survival Study (4S) study group Third report of the expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III, or ATP III) final report. Circulation. 106:2002;3143-3420
19. The Scandanavian Simvastatin Survival Study (4S) study group Summary of the second report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel II). JAMA. 269:1993;3015-3023
20. Enos W.F., Holmes R.H., Beyer J. Coronary disease among United States soldiers killed in action in Korea. Preliminary report. By William F. Enos, Robert H. Holmes and James Beyer. JAMA. 256:1986;2859-2862
21. McNamara J.J., Molot M.A., Stremple J.F., Cutting R.T. Coronary artery disease in combat casualties in Vietnam. JAMA. 216:1971;1185-1187
22. The Pathobiological Determinants of Atherosclerosis in Youth (PDAY) Research Group Relationship of atherosclerosis in young men to serum lipoprotein cholesterol concentrations and smoking. A preliminary report from the Pathobiological Determinants of Atherosclerosis in Youth (PDAY) Research Group. JAMA. 264:1990;3018-3024
23. The Pathobiological Determinants of Atherosclerosis in Youth (PDAY) Research Group Natural history of aortic and coronary atherosclerotic lesions in youth. Findings from the PDAY Study. Pathobiological Determinants of Atherosclerosis in Youth (PDAY) Research Group. Arterioscler. Thromb. 13:1993;1291-1298
24. Tuzcu E.M., Kapadia S.R., Tutar E., Ziada K.M., Hobbs R.E., McCarthy P.M., et al. High prevalence of coronary atherosclerosis in asymptomatic teenagers and young adults: evidence from intravascular ultrasound. Circulation. 103:2001;2705-2710
25. Newman W.P., Freedman D.S., Voors A.W., Gard P.D., Srinivasan S.R., Cresanta J.L., et al. Relation of serum lipoprotein levels and systolic blood pressure to early atherosclerosis: the Bogalusa Heart Study. N. Engl. J. Med. 314:1986;138-144
26. Holme I., Solberg L.A., Weissfeld L., Helgeland A., Hjermann I., Leren P., et al. Coronary risk factors and their pathway of action through coronary raised lesions, coronary stenoses and coronary death: multivariate statistical analysis of an autopsy series: the Oslo Study. Am. J. Cardiol. 55:1985;40-47
27. Romm P.A., Green C.E., Reagan K., Rackley C.E. Relation of serum lipoprotein cholesterol levels to presence and severity of angiographic coronary artery disease. Am. J. Cardiol. 67:1991;479-483
28. Kempen H.J., van Gent C.M., Buytenhek R., Buis B. Association of cholesterol concentrations in low-density lipoprotein, high-density lipoprotein, and high-density lipoprotein subfractions, and of apolipoproteins AI and AII, with coronary stenosis and left ventricular function. J. Lab. Clin. Med. 109:1987;19-26
29. Dahlen G.H., Guyton J.R., Attar M., Farmer J.A., Kautz J.A., Gotto A.M. Jr. Association of levels of lipoprotein Lp(a), plasma lipids, and other lipoproteins with coronary artery disease documented by angiography. Circulation. 74:1986;758-765
30. Manninen V., Elo M.O., Frick M.H., Haapa K., Heinonen O.P., Heinsalmi P., et al. Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study. JAMA. 260:1988;641-651
31. Howes L.G., Simons L.A. Efficacy of drug intervention for lipids in the prevention of coronary artery disease. Aust. N. Z. J. Med. 24:1994;107-112
32. Heart Protection Study collaboration group MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomized placebo-controlled trial. Lancet. 360:2002;7-22
33. Bucher H.C., Griffith L.E., Guyatt G. Systematic review on the risk and benefit of different cholesterol-lowering interventions. Arterioscler. Thromb. Vasc. Biol. 19:1999;187-195
34. Miettinen T.A., Pyorala K., Olsson A.G., Musliner T.A., Cook T.J., Faergeman O., et al. Cholesterol-lowering therapy in women and elderly patients with myocardial infarction or angina pectoris: findings from the Scandinavian Simvastatin Survival Study (4S). Circulation. 96:1997;4211-4218
35. Smith G.D., Song F., Sheldon T.A. Cholesterol lowering and mortality: the importance of considering initial level of risk. [correction appears in BMJ 306 (1993) 1648] BMJ. 306:1993;1367-1373
36. LaRosa J.C., He J., Vupputuri S. Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials. JAMA. 282:1999;2340-2346
37. http://www.nhlbi.nih.gov/guidelines/cholesterol/chap_3.pdf.
38. Wilson P.W.F., D'Agostino R.B., Levy D., Belanger A.M., Silbershatz H., Kannel W.B. Prediction of coronary heart disease using risk factor categories. Circulation. 97:1998;1837-1847
39. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 285:2001;2486-2497
40. Sawayama Y., Shimizu C., Maeda N., Tatsukawa M., Kinukawa N., Koyanagi S., et al. Effects of probucol and pravastatin on common carotid atherosclerosis in patients with asymptomatic hypercholesterolemia. Fukuoka Atherosclerosis Trial (FAST). J. Am. Coll. Cardiol. 39:2002;610-616
41. Pignone M., Phillips C., Mulrow C. Use of lipid lowering drugs for primary prevention of coronary heart disease: meta-analysis of randomized trials. BMJ. 321:2000;983-986
42. Lloyd-Jones D.M., O'Donnell C.J., D'Agostino R.B., Massaro J., Silbershatz H., Wilson P.W. Applicability of cholesterol-lowering primary prevention trials to a general population: the Framingham heart study. Arch. Intern. Med. 161:2001;949-954
43. The Post Coronary Artery Bypass Graft Trial Investigators The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts. N. Engl. J. Med. 336:1997;153-162
44. Pitt B., Waters D., Brown W.V., van Boven A.J., Schwartz L., Title L.M., et al. Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. Atorvastatin versus Revascularization Treatment Investigators. N. Engl. J. Med. 341:1999;70-76
45. Smilde T.J., van Wissen S., Wollersheim H., Trip M.D., Kastelein J.J., Stalenhoef A.F. Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomised, double-blind trial. Lancet. 357:2001;577-581
46. Pedersen T.R. Aggressive lipid-lowering therapy: a clinical imperative. Eur. Heart J. 19:1998;M15-M21. (Suppl. M)
47. Pedersen T.R., Kjekshus J., Olsson A.G., Cook T.J. 4S results support AHA guidelines to reduce LDL-cholesterol to less than 100 mg/dl inpatients with CHD. Circulation. 96(Suppl. I):1997;717
48. Wannamethee S.G., Shaper A.G., Walker M. Physical activity and mortality in older men with diagnosed coronary heart disease. Circulation. 102:2000;1358-1363
49. Leon A.S., Connett J. Physical activity and 10.5 year mortality in the Multiple Risk Factor Intervention Trial (MRFIT). Int. J. Epidemiol. 20:1991;690-697
50. Rosengren A., Wilhelmsen L. Physical activity protects against coronary death and deaths from all causes in middle-aged men. Evidence from a 20-year follow-up of the primary prevention study in Goteborg. Ann. Epidemiol. 7:1997;69-75
51. Kokkinos P.F., Fernhall B. Physical activity and high density lipoprotein cholesterol levels: what is the relationship? Sports Med. 28:1999;307-314
52. Kokkinos P.F., Holland J.C., Narayan P., Colleran J.A., Dotson C.O., Papademetriou V. Miles run per week and high-density lipoprotein cholesterol levels in healthy, middle-aged men. A dose-response relationship. Arch. Intern. Med. 155:1995;415-420
53. Stefanick M.L., Mackey S., Sheehan M., Ellsworth N., Haskell W.L., Wood P.D. Effects of diet and exercise in men and postmenopausal women with low levels of HDL cholesterol and high levels of LDL cholesterol. N. Engl. J. Med. 339:1998;12-20
54. Davignon J., Montigny M., Dufour R. HMG-CoA reductase inhibitors: a look back and a look ahead. Can. J. Cardiol. 8:1992;843-864
55. Reihner E., Rudling M., Stahlberg D., Berglund L., Ewerth S., Bjorkhem I., et al. Influence of pravastatin, a specific inhibitor of HMG-CoA reductase, on hepatic metabolism of cholesterol. N. Engl. J. Med. 323:1990;224-228
56. Arad Y., Ramakrishnan R., Ginsberg H.N. Effects of lovastatin therapy on very-low-density lipoprotein triglyceride metabolism in subjects with combined hyperlipidemia: evidence for reduced assembly and secretion of triglyceride-rich lipoproteins. Metabolism. 41:1992;487-493
57. Sacks F.M., Pfeiffer M.A., Moye L.A., Rouleau J.L., Rutherford J.D., Cole T.G., et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels: cholesterol and recurrent events trial investigators. N. Engl. J. Med. 335:1996;1001-1009
58. Packard C.J. Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS). Circulation. 87:1998;1440-1445
59. Takemoto M., Liao J.K. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors. Arterioscler. Thromb. Vasc. Biol. 21:2001;1712-1719
60. McFarlane S.I., Muniyappa R., Francisco R., Sowers J.R. Clinical review 145: pleiotropic effects of statins: lipid reduction and beyond. J. Clin. Endocrinol. Metab. 87:2002;1451-1458
61. Liao J.K., Bettmann M.A., Sandor T., Tucker J.I., Coleman S.M., Creager M.A. Differential impairment of vasodilator responsiveness of peripheral resistance and conduit vessels in humans with atherosclerosis. Circ. Res. 68:1991;1027-1034
62. Rikitake Y., Kawashima S., Takeshita S., Yamashita T., Azumi H., Yasuhara M., et al. Anti-oxidative properties of fluvastatin, an HMG-CoA reductase inhibitor, contribute to prevention of atherosclerosis in cholesterol-fed rabbits. Atherosclerosis. 154:2001;87-96
63. Lopez S., Peiretti F., Bonardo B., Juhan-Vague I., Nalbone G. Effect of atorvastatin and fluvastatin on the expression of plasminogen activator inhibitor type-1 in cultured human endothelial cells. Atherosclerosis. 152:2000;359-366
64. Hernandez-Perera O., Perez-Sala D., Navarro-Antolin J., Sanchez-Pascuala R., Hernandez G., Diaz C., et al. Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells. J. Clin. Invest. 101:1998;2711-2719
65. Tamai O., Matsuoka H., Itabe H., Wada Y., Kohno K., Imaizumi T. Single LDL apheresis improves endothelium-dependent vasodilatation in hypercholesterolemic humans. Circulation. 95:1997;76-82
66. Laufs U., La Fata V., Plutzky J., Liao J.K. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation. 97:1998;1129-1135
67. Essig M., Nguyen G., Prie D., Escoubet B., Sraer J.D., Friedlander G. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors increase fibrinolytic activity in rat aortic endothelial cells: role of geranylgeranylation and Rho proteins. Circ. Res. 83:1998;683-690
68. Plenge J.K., Hernandez T.L., Weil K.M., et al. Simvastatin lowers C-reactive protein within 14 days: an effect independent of LDL cholesterol reduction. Circulation. 106:2002;1447-1452
69. Albert M.A., Danielson E., Rifai N. for PRINCE Investigators Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE). A randomized trial and cohort study. JAMA. 286:2001;64-70
70. Mabuchi H., Haba T., Tatami R., Miyamoto S., Sakai Y., Wakasugi T., et al. Effects of an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase on serum lipoproteins and ubiquinone-10 levels in patients with familial hypercholesterolemia. N. Engl. J. Med. 305:1981;478-482
71. Bakker-Arkema R.G., Davidson M.H., Goldstein R.J., Davignon J., Isaacsohn J.L., Weiss S.R., et al. Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia. JAMA. 275:1996;128-133
72. Davidson M.H., Stein E.A., Dujovne C.A., Hunninghake D.B., Weiss S.R., Knopp R.H., et al. The efficacy and six-week tolerability of simvastatin 80 and 160 mg per day. Am. J. Cardiol. 79:1997;38-42
73. Crouse J.R. III, Frohlich J., Ose L., Mercuri M., Tobert J.A. Effects of high doses of simvastatin and atorvastatin on high-density lipoprotein cholesterol and apolipoprotein A-I. Am. J. Cardiol. 83:1999;1476-1477
74. Kastelein J.J., Isaacsohn J.L., Ose L., Hunninghake D.B., Frohlich J., Davidson M.H., et al. Comparison of effects of simvastatin versus atorvastatin on high-density lipoprotein cholesterol and apolipoprotein A-I levels. Am. J. Cardiol. 86:2000;221-223
75. Salonen R., Nyyssonen K., Porkkala-Sarataho E., Salmen J.J. The Kuopio Atherosclerosis Prevention Study (KAPS): effect of pravastatin treatment on lipids, oxidation resistance of lipoproteins, and atherosclerotic progression. Am. J. Cardiol. 76:1995;34-39
76. Dupuis J., Tardif J.C., Theroux P. Cholesterol reduction rapidly improves endothelial function after acute coronary syndromes. The RECIFE (Reduction of Cholesterol in Ischemia and Function of the Endothelium) trial. Circulation. 99:1999;3227-3233
77. Kaesemeyer W.H., Caldwell R.B., Huang J., Caldwell R.W. Pravastatin sodium activates endothelial nitric oxide synthase independent of its cholesterol-lowering actions. J. Am. Coll. Cardiol. 33:1999;234-241
78. Dangas G., Badimon J.J., Smith D.A., Unger A.H., Levine D., Shao J.H. Pravastatin therapy in hyperlipidemia effects on thrombus formation and the systemic hemostatic profile. J. Am. Coll. Cardiol. 33:1999;1294-1304
79. Kempen H.J.M., Vermeer M., de Wit E., Havekes L.M. Vastatins inhibit cholesterol ester accumulation in human monocyte-derived macro phages. Arterioscler. Thromb. 11:1991;146-153
80. Weber C., Erl W., Weber K.S., Weber P.C. HMG-CoA reductase inhibitors decrease CD11b expression and CD11b-dependent adhesion of monocytes to endothelium and reduce increased adhesiveness of monocytes isolated from patients with hypercholesterolemia. J. Am. Coll. Cardiol. 30:1997;1212-1217
81. Negre-Aminou P., van Vliet A.K., van Erck M., van Thiel G.C., van Leeuwen R.E., Cohen L.H. Inhibition of proliferation of human smooth muscle cells by various HMG-CoA reductase inhibitors; comparison with other human cell types. Biochim. Biophys. Acta. 1345:1997;259-268
82. Igarashi M., Takeda Y., Mori S., Ishibashi N., Kamatsu E., Takahashi K. Suppression of neointimal thickening by a newly developed HMG-CoA reductase inhibitor, BAYw6228, and its inhibitory effect on vascular smooth muscle cell growth. Br. J. Pharmacol. 120:1997;1172-1178
83. Notarbartolo A., Davi G., Averna M., Barbagallo C.M., Ganci A., Giammarresi C. Inhibition of thromboxane biosynthesis and platelet function by simvastatin in type IIa hypercholesterolemia. Arterioscler. Thromb. Vasc. Biol. 15:1995;247-251
84. Mayer J., Eller T., Brauer P., Solleder E.M., Schafer R.M., Keller F. Effects of long-term treatment with lovastatin on the clotting system and blood platelets. Ann. Hematol. 64:1992;196-201
85. Sandset P.M., Lund H., Norseth J., Abildgaard U., Ose L. Treatment with hydroxymethylglutaryl coenzyme A reductase inhibitors in hyper cholesterolemia induces changes in the components of the extrinsic coagulation system. Arterioscler. Thromb. 11:1991;138-145
86. Velussi M., Cemigi A.M., Tortal C., Merni M. Atorvastatin for the management of type 2 diabetic patients with dyslipidemia. A mid-term (9 months) treatment experience. Diabetes Nutr. Metab. 12:1999;407-412
87. Tsuda Y., Satoh K., Kitadai M., Takahashi T., Izumi Y., Hasomi N. Effects of pravastatin sodium and simvastatin on plasma fibrinogen level and blood rheology in type II hyperlipoproteinemia. Atherosclerosis. 122:1996;225-233
88. Koenig W., Hehr R., Ditshuneit H., Kuhn K., Ernst E., Rosenthal J. Lovastatin alters blood rheology in primary hyperlipoproteinemia: dependence on lipoprotein (a)? J. Clin. Pharmacol. 32:1992;539-545
89. Isaacsohn J.L., Setaro J.F., Nicholas C., Davey J.A., Diotalevi L.J., Christianson D.S. Effects of lovastatin therapy on plasminogen activator inhibitor-1 antigen levels. Am. J. Cardiol. 73:1994;5-7
90. Puccetti L., Pasqui A.L., Pastorelli M., Bova G., Cercignani M., Palazzuoli A., et al. Time-dependent effect of statins on platelet function in hypercholesterolaemia. Eur. J. Clin. Invest. 32:2002;901-908
91. Puccetti L., Bruni F., Bova G., Cercignani M., Palazzuoli A., Console E., et al. Effect of diet and treatment with statins on platelet-dependent thrombin generation in hypercholesterolemic subjects. Nutr. Metab. Cardiovasc. Dis. 11:2001;378-387
92. Ridker P.M., Rifal N., Pfeffer M.A., Sacks F., Braunwald E. Long-term effects of pravastatin on plasma concentration of C reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators. Circulation. 100:1999;230-235
93. Sposito A.C., Mansur A.P., Coelho O.R., Nicolau J.C., Ramires J.A.F. Additional reduction in blood pressure after cholesterol-lowering treatment by statins (lovastatin or pravastatin) in hypercholesterolemic patients using angiotensin-converting enzyme inhibitors (enalapril or lisinopril). Am. J. Cardiol. 83:1999;1497-1499
94. Lee T.M., Su S.F., Tsai C.H. Effect of pravastatin on proteinuria in patients with well controlled hypertension. Hypertension. 40:2002;67-73
95. Sever P.S., Dahlof B., Poulter N.R., Wedel H., Beevers G., Caulfield M., et al. ASCOT investigators Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet. 361:2003;1149-1158
96. Jackson P.R., Wallis E.J., Haq I.U., Ramsay L.E. Statins for primary prevention: at what coronary risk is safety assured? Br J. Clin. Pharmacol. 52:2001;439-446
97. Gotto A.M. Jr. Treating hypercholesterolemia: looking forward. Clin. Cardiol. 26(1 Suppl. 1):2003 Jan.;I21-I28
98. Cheng-Lai A. Rosuvastatin: a new HMG-CoA reductase inhibitor for the treatment of hypercholesterolemia. Heart Dis. 5:2003;72-78
99. Paoletti R., Fahmy M., Mahla G., Mizan J., Southworth H. Rosuvastatin demonstrates greater reduction of low-density lipoprotein cholesterol compared with pravastatin and simvastatin in hypercholesterolaemic patients: a randomized, double-blind study. J. Cardiovasc. Risk. 8:2001;383-390
100. Davidson M., Ma P., Stein E.A., Gotto A.M. Jr., Raza A., Chitra R., et al. Comparison of effects on low-density lipoprotein cholesterol and high-density lipoprotein cholesterol with rosuvastatin versus atorvastatin in patients with type IIa or IIb hypercholesterolemia. Am. J. Cardiol. 89:2002;268-275
101. Olsson A.G., Istad H., Luurila O., Ose L., Stender S., Tuomilehto J., et al. Effects of rosuvastatin and atorvastatin compared over 52 weeks of treatment in patients with hypercholesterolemia. Am. Heart J. 144:2002;1044-1051
102. Insull W. Jr., Isaacsohn J., Kwiterovich P., Ra P., Brazg R., Dujovne C., et al. Efficacy and safety of cerivastatin 0.8 mg in patients with hypercholesterolaemia: the pivotal placebo-controlled clinical trial. Cerivastatin Study Group. J. Int. Med. Res. 28:2000;47-68
103. Davidson M.H., Stein E.A., Hunninghake D.B., Ose L., Dujovne C.A., Insull W. Jr., et al. Lipid-altering efficacy and safety of simvastatin 80 mg/day: worldwide long-term experience in patients with hypercholesterolemia. Nutr. Metab. Cardiovasc. Dis. 10:2000;253-262
104. Backes J.M., Howard P.A. Association of HMG-CoA reductase inhibitors with neuropathy. Ann. Pharmacother. 37:2003;274-278
105. Lennernas H., Fager G. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences. Clin. Pharmacokinet. 32:1997;403-425
106. Spach D.H., Bauwens J.E., Clark C.D., Burke W.G. Rhabdomyolysis associated with lovastatin and erythromycin use. West. J. Med. 154:1991;213-215
107. Neuvonen P.J., Jalava K.M. Itraconozole drastically increases plasma concentration of lovastatin and lovastatin acid. Clin. Pharmacol. Ther. 60:1996;54-61
108. Kantola T., Kivisto K.T., Neuvonen P.J. Effect of itraconozole on the pharmacokinetics of atorvastatin. Clin. Pharmacol. Ther. 64:1998;58-65
109. Hanston P.D., Horn J.R. Drug interactions with HMG Co A reductase inhibitors. Drug Interact. Newsl. 1998;103-106
110. Olbricht C., Wanner C., Eisenhauer T., Kliem V., Doll R., Boddaert M., et al. Accumulation of lovastatin, but not pravastatin, in the blood of cyclosporine-treated kidney graft patients after multiple doses. Clin. Pharmacol. Ther. 62:1997;311-321
111. Gruer P.J., Vega J.M., Mercuri M.F., Dobrinska M.R., Tobert J.A. Concomitant use of cytochrome P450 3A4 inhibitors and simvastatin. Am. J. Cardiol. 84:1999;811-815
112. Canner P.L., Berge K.G., Wenger N.K., Stamler J., Friedman L., Prineas R.J., et al. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J. Am. Coll. Cardiol. 8:1986;1245-1255
113. Knopp R.H., Ginsberg J., Albers J.J., Hoff C., Ogilvie J.T., Warnick G.R., et al. Contrasting effects of unmodified and time-release forms of niacin on lipoproteins in hyperlipidemic subjects: clues to mechanism of action of niacin. Metab. Clin. Exper. 34:1985;642-650
114. Illingworth D.R., Stein E.A., Mitchel Y.B., Dujovne C.A., Frost P.H., Knopp R.H., et al. Comparative effects of lovastatin and niacin in primary hypercholesterolemia. A prospective trial. Arch. Intern. Med. 154:1994;1586-1595
115. Gibbons L.W., Gonzalez V., Gordon N., Grundy S. The prevalence of side effects with regular and sustained-release nicotinic acid. Am. J. Med. 99:1995;378-385
116. Capuzzi D.M., Guyton J.R., Morgan J.M., Goldberg A.C., Kreisberg R.A., Brusco O.A., et al. Efficacy and safety of an extended-release niacin (Niaspan): a long-term study. Am. J. Cardiol. 82:1998;74U-81U
117. Elam M.B., Hunninghake D.B., Davis K.B., Garg R., Johnson C., Egan D., et al. Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease: the ADMIT study: a randomized trial. Arterial Disease Multiple Intervention Trial. JAMA. 284:2000;1263-1270
118. McKenney J.M., Proctor J.D., Harris S., Chinchili V.M. A comparison of the efficacy and toxic effects of sustained- vs. immediate-release niacin in hypercholesterolemic patients. JAMA. 271:1994;672-677
119. Morgan J.M., Capuzzi D.M., Guyton J.R. A new extended-release niacin (Niaspan): efficacy, tolerability, and safety in hypercholesterolemic patients. Am. J. Cardiol. 82:1998;29U-34U
120. Blankenhorn D.H., Nessim S.A., Johnson R.L., Sanmarco M.E., Azen S.P., Cashin-Hemphill L. Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. JAMA. 257:1987;3233-3240
121. Kane J.P., Malloy M.J., Ports T.A., Phillips N.R., Diehl J.C., Havel R.J. Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens. JAMA. 264:1990;3007-3012
122. Carlson L.A., Rosenhamer G. Reduction of mortality in the Stockholm Ischaemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid. Acta Med. Scand. 223:1988;405-418
123. Guyton J.R., Capuzzi D.M. Treatment of hyperlipidemia with combined niacin-statin regimens. Am. J. Cardiol. 82:1998;82U-84U
124. Guyton J.R., Goldberg A.C., Kreisberg R.A., Sprecher D.L., Superko H.R., O'Connor C.M. Effectiveness of once-nightly dosing of extended-release niacin alone and in combination for hypercholesterolemia. Am. J. Cardiol. 82:1998;737-743
125. Knopp R.H. Drug treatment of lipid disorders. N. Engl. J. Med. 34:1999;498-511
126. Ide T., Oku H., Sugano M. Reciprocal responses to clofibrate in ketogenesis and triglyceride and cholesterol secretion in isolated rat liver. Metabolism. 31:1982;1065-1072
127. Schoonjans K., Staels B., Auwerx J. Role of the peroxisome proliferator-activated receptor (PPAR) in mediating the effects of fibrates and fatty acids on gene expression. J. Lipid Res. 37:1996;907-925
128. Auwerx J., Schoonjans K., Fruchart J.C., Staels B. Regulation of triglyceride metabolism by PPARs: fibrates and thiazolidinediones have distinct effects. J. Atheroscler. Thromb. 3:1996;81-89
129. Fruchart J.C., Brewer H.B. Jr., Leitersdorf E. Consensus for the use of fibrates in the treatment of dyslipoproteinemia and coronary heart disease. Fibrate Consensus Group. Am. J. Cardiol. 81:1998;912-927
130. Auwerx J., Schoonjans K., Fruchart J.C., Staels B. Transcriptional control of triglyceride metabolism: fibrates and fatty acids change the expression of the LPL and apo C-III genes by activating the nuclear receptor PPAR. Atherosclerosis. 124:1996;S29-S37. [Suppl.]
131. Wood D., De Backer G., Faergeman O., Graham I., Mancia G., Pyorala K. Prevention of coronary heart disease in clinical practice. Summary of recommendations of the second joint task force of european and other societies on coronary prevention. Blood Press. (5-6):1998;262-269
132. Spencer C.M., Barradell L.B. Gemfibrozil, A reappraisal of its pharmacological properties and place in the management of dyslipidaemia. Drugs. 51:1996;982-1018
133. Frick M.H., Elo O., Haapa K., Heinonen O.P., Heinsalmi P., Helo P., et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N. Engl. J. Med. 317:1987;1237-1245
134. Anonymous A co-operative trial in the primary prevention of ischaemic heart disease using clofibrate. Report from the Committee of Principal Investigators. Br. Heart J. 40:1978;1069-1118
135. Rubins H.B., Robins S.J., Collins D., Fye C.L., Anderson J.W., Elam M.B., et al. The veterans affairs high-density lipoprotein cholesterol intervention Trial Study Group. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N. Engl. J. Med. 341:1999;410-418
136. Palmer R.H. Effects of fibric acid derivatives on biliary lipid composition. Am. J. Med. 83:1987;37-43
137. Bays H.E., Dujovne C.A. Drug interactions of lipid-altering drugs. Drug Saf. 19:1998;355-371
138. Pauciullo P., Marotta G., Rubba P., Cortese C., Caruso M.G., Gnasso A., et al. Serum lipoproteins, apolipoproteins and very low density lipoprotein subfractions during 6-month fibrate treatment in primary hypertriglyceridaemia. J. Intern. Med. 228:1990;425-430
139. Leaf D.A., Connor W.E., Illingworth D.R., Bacon S.P., Sexton G. The hypolipidemic effects of gemfibrozil in type V hyperlipidemia. A double-blind, crossover study. JAMA. 262:1989;3154-3160
140. Grundy S.M., Ahrens E.H., Salen G. Interruption of the enterohepatic circulation of bile acids in man: comparative effects of cholestyramine and ileal exclusion on cholesterol metabolism. J. Lab. Clin. Med. 178:1971;94-121
141. Shepherd J., Packard C.J., Bicker S., Lawrie T.D.V., Morgan H.G. Cholestyramine promotes receptor-mediated low-density-lipoprotein catabolism. N. Engl. J. Med. 302:1980;1219-1222
142. Wiklund O., Angelin B., Fager G., Eriksson M., Olofsson S.O., Berglund L., et al. Treatment of familial hypercholesterolaemia: a controlled trial of the effects of pravastatin or cholestyramine therapy on lipoprotein and apolipoprotein levels. J. Intern. Med. 228:1990;241-247
143. Brensike J.F., Levy R.I., Kelsey S.F., Passamani E.R., Richardson J.M., Loh I.K., et al. Effects of therapy with cholestyramine on progression of coronary arteriosclerosis: results of the NHLBI Type II Coronary Intervention Study. Circulation. 69:1984;313-324
144. Schectman G., Hiatt J. Evaluation of the effectiveness of lipid-lowering therapy (bile acid sequestrants, niacin, psyllium, and lovastatin) for treating hypercholesterolemia in veterans. Am. J. Cardiol. 71:1993;759-765
145. Hunninghake D.B., Stein E.A., Fraser Bremner W., Greenland P., Demke D.M., Oliphant T.H. Dose-response study of colestipol tablets in patients with moderate hypercholesterolemia. Am. J. Ther. 2:1995;180-189
146. Superko H.R., Greenland P., Manchester R.A., Andreadis N.A., Schectman G., West N.H., et al. Effectiveness of low-dose colestipol therapy in patients with moderate hypercholesterolemia. Am. J. Cardiol. 70:1992;135-140
147. Vecchio T.J., Linden C.V., O'Connell M.J., Heilman J. Comparative efficacy of colestipol and clofibrate in type IIa hyperlipoproteinemia. Arch. Intern. Med. 142:1982;721-723
148. Knapp H.H., Schrott H., Ma P., Knopp R., Chin B., Gaziano J.M., et al. Efficacy and safety of combination simvastatin and colesevelam in patients with primary hypercholesterolemia. Am. J. Med. 110:2001;352-360
149. Denke M.A., Grundy S.M. Efficacy of low-dose cholesterol-lowering drug therapy in men with moderate hypercholesterolemia. Arch. Intern. Med. 155:1995;393-399
150. Andrade S.E., Walker A.M., Gottlieb L.K., Hollenberg N.K., Testa M.A., Saperia G.M., et al. Discontinuation of antihyperlipidemic drugs: do rates
151. Hunninghake D.B., Stein E.A., Fraser Bremner W., Greenland P., Demke D.M., Oliphant T.H. Dose-response study of colestipol tablets in patients with moderate hypercholesterolemia. Am. J. Ther. 2:1995;180-189
152. Dorr A.E., Gundersen K., Schneider J.C. Jr., Spencer T.W., Martin W.B. Colestipol hydrochloride in hypercholesterolemic patients: effect on serum cholesterol and mortality. J. Chronic. Dis. 31:1978;5-14
153. Davidson M.H., Dillon M.A., Gordon B., Jones P., Samuels J., Weiss S., et al. Colesevelam hydrochloride (cholestagel): a new, potent bile acid sequestrant associated with a low incidence of gastrointestinal side effects. Arch. Intern. Med. 159:1999;1893-1900
154. Ezetimibe (Zetia) prescribing information. Merck/Schering-plough pharmaceuticals, North Wales PA 19454. October 2002
155. Sudhop T., von Bergmann K. Cholesterol absorption inhibitors for the treatment of hypercholesterolaemia. Drugs. 62:2002;2333-2347
156. Dujovne C.A., Ettinger M.P., McNeer J.F., Lipka L.J., LeBeaut A.P., Suresh R., et al. Efficacy and safety of a potent new selective cholesterol absorption inhibitor, ezetimibe, in patients with primary hypercholesterolemia. Am. J. Cardiol. 90:2002;1092-1097
157. Gagne C., Bays H.E., Weiss S.R., Mata P., Quinto K., Melino M., et al. Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia. Am. J. Cardiol. 90(15):2002 Nov.;1084-1091
158. Kosoglou T., Meyer I., Veltri E.P., Statkevich P., Yang B., Zhu Y., et al. Pharmacodynamic interaction between the new selective cholesterol absorption inhibitor ezetimibe and simvastatin. Br. J. Clin. Pharmacol. 54:2002;309-319
159. Braun L.T., Davidson M.H. Cholesterol-lowering drugs bring benefits to high-risk populations even when LDL is normal. J. Cardiovasc. Nurs. 18:2003;44-49
160. Pearson T.A. The undertreatment of LDL-cholesterol: addressing the challenge. Int. J. Cardiol. 74(Suppl. 1):2000;S23-S28
161. Pearson T.A., Laurora I., Chu H., Kafonek S. The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch. Intern. Med. 160:2000;459-467